Analyst Price Target is C$15.00
▲ +41.51% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for BriaCell Therapeutics in the last 3 months. The average price target is C$15.00, with a high forecast of C$15.00 and a low forecast of C$15.00. The average price target represents a 41.51% upside from the last price of C$10.60.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in BriaCell Therapeutics. This N/A consensus rating has held steady for over two years.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Read More